Processa Pharmaceuticals Secures $7M for Clinical Trials

Introduction

Processa Pharmaceuticals Inc (Nasdaq: PCSA) is a clinical-stage biotechnology company headquartered in Hanover, Maryland. As of July 9, 2025, the stock closed at $0.2749 per share, reflecting a 29.43% increase on a volume of 4,678,607 shares traded. The company focuses on addressing unmet medical needs by in-licensing therapies with existing clinical or scientific data and advancing them through development programs.

Corporate Structure

Founded in October 2017, Processa Pharmaceuticals employs between 11 and 50 professionals. Its leadership and advisory team includes:

• Geraldine Pannu, Independent Board Director
• Michael Floyd, BioPharma entrepreneur
• Russell Skibsted, Executive Vice President, Chief Financial Officer & Chief Business Officer at Rockwell Medical, Inc.
• Patrick Lin, Managing Partner at Primarius Capital and co-founder of Processa Pharmaceuticals

The internal development team has participated in over 30 FDA drug approvals and more than 100 FDA meetings, utilizing regulatory science expertise.

Biotechnology by National Cancer Institute

Developments and News

On June 17, 2025, Processa announced the pricing of a public offering of $7 million, consisting of 28 million shares of common stock (or pre-funded warrants) with attached common warrants exercisable at $0.25 per share. Net proceeds are intended to support the Phase 2 clinical trial for NGC-Cap (PCS6422) and general corporate purposes.

In mid-June, the company signed a binding term sheet with Intact Therapeutics granting an exclusive option to license PCS12852, a 5-HT4 receptor agonist for the treatment of gastroparesis. The agreement includes up to $452.5 million in milestone payments and double-digit royalties on worldwide net sales (excluding South Korea), with Processa retaining a 3.5% equity stake and sharing 60% of cash payments with its licensor.

On May 30, 2025, Processa presented three abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, which included data on:

• An adaptive Phase 2 trial of eniluracil combined with capecitabine in metastatic breast cancer (Abstract TPS1133)
• Phase 1b safety and efficacy results for NGC-Cap (Abstract e15152)
• Preclinical dose-escalation strategy for PCS11T, an SN-38 pro-drug (Abstract e15023)

In a Form 8-K filed on July 1, 2025, Processa reported material agreements and significant corporate actions under Sections 1.01, 7.01, and 9.01. A Schedule 13G, filed on June 24, 2025, disclosed that CVI Investments, Inc. holds 2,663,078 shares (9.9% of outstanding common stock) with shared voting and dispositive power.

Financial and Strategic Analysis

The stock’s 29.43% rise on July 9, 2025, indicates market interest following recent clinical and licensing milestones. The $7 million equity raise at $0.25 per share is intended to support the Phase 2 trial of PCS6422, which combines eniluracil and capecitabine in metastatic breast cancer. The Intact Therapeutics agreement for PCS12852 allows Processa to focus its resources on its oncology pipeline while monetizing a non-oncology asset. The company’s strategy emphasizes acquiring late-stage candidates, defining complete FDA development paths, and out-licensing before or after pivotal trials to optimize capital efficiency.

Market Position and Industry Context

Processa operates in the oncology and specialty therapy sectors, focusing on life-threatening and chronic diseases with high unmet needs. The company combines active molecules with regulatory science to improve safety and efficacy, aligning with industry trends toward precision dosing. Partnerships with placement agents, such as H.C. Wainwright & Co., and licensing discussions demonstrate its capability to attract external capital and strategic collaborations. The approximately 9.9% stake held by CVI Investments indicates institutional interest, which may also influence corporate governance.

TL;DR

PCSA shares increased 29.43% to $0.2749 on July 9, 2025, influenced by a licensing option with Intact Therapeutics for PCS12852, valued up to $452.5 million, and a $7 million public offering closing on June 18, 2025. Clinical advancements include three ASCO abstracts on NGC-Cap and PCS11T. Upcoming catalysts include Phase 2 readouts for PCS6422 and potential warrant exercises from the June offering. Future milestones depend on trial data, regulatory submissions, and partnership developments.